## Smoking, quitting and mortality in an elderly cohort of 56000 Hong Kong Chinese

Tai Hing Lam, Zhi Bin Li, Sai Yin Ho, Wai Man Chan, Kin Sang Ho, May Ked Tham, Benjamin J Cowling, C Mary Schooling and Gabriel M Leung

Tob. Control 2007;16;182-189 doi:10.1136/tc.2006.019505

Updated information and services can be found at:
http://tobaccocontrol.bmj.com/cgi/content/full/16/3/182

These include:
References This article cites 25 articles, 15 of which can be accessed free at: http://tobaccocontrol.bmj.com/cgi/content/full/16/3/182\#BIBL

2 online articles that cite this article can be accessed at:
http://tobaccocontrol.bmj.com/cgi/content/full/16/3/182\#otherarticles
Rapid responses You can respond to this article at:
http://tobaccocontrol.bmj.com/cgi/eletter-submit/16/3/182
Email alerting
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Notes

To order reprints of this article go to:
http://journals.bmj.com/cgi/reprintform
To subscribe to Tobacco Control go to:
http://journals.bmj.com/subscriptions/

## RESEARCH PAPER

# Smoking, quitting and mortality in an elderly cohort of 56000 Hong Kong Chinese 

Tai Hing Lam, Zhi Bin Li, Sai Yin Ho, Wai Man Chan, Kin Sang Ho, May Ked Tham, Benjamin J Cowling, C Mary Schooling, Gabriel M Leung

See end of article for authors' affiliations

## Correspondence to:

 Professor T H Lam, Department of Community Medicine, School of Public Health, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong;commed@hkucc.hku.hk
Received 3 December 2006 Accepted 7 March 2007


#### Abstract

Background: Although the harms of smoking are well established, it is unclear how they extend into old age in the Chinese. Aim: To examine the relationship of smoking with all-cause and major cause-specific mortality in elderly Chinese men and women, respectively, in Hong Kong. Methods: Mortality by smoking status was examined in a prospective cohort study of 56167 (18 749 men, 37416 women) Chinese aged $\geqslant 65$ years enrolled from 1998 to 2000 at all the 18 elderly health centres of the Hong Kong Government Department of Health. Results: After a mean follow-up of 4.1 years, 1848 male and 2035 female deaths occured among 54214 subjects ( $96.5 \%$ successful follow-up). At baseline, more men than women were current smokers ( $20.3 \%$ vs $4.0 \%$ ) and former smokers ( $40.8 \%$ vs $7.9 \%$ ). The adjusted RRs ( $95 \% \mathrm{CI}$ ) for all-cause mortality in former and current smokers, compared with never smokers, were 1.39 ( 1.23 to 1.56 ) and 1.75 ( 1.53 to 2.00 ) in men and 1.43 ( 1.25 to 1.64 ) and $1.38(1.14$ to 1.68 ) in women, respectively. For current smokers, the RRs ( $95 \%$ $\mathrm{Cl})$ for all-cause mortality were 1.59 ( 1.39 to 1.82 ), 1.72 ( 1.48 to 2.00 ) and 1.84 ( 1.43 to 2.35 ) for daily consumption of 1-9, 10-20 and $>21$ cigarettes, respectively (p for trend $<0.001$ ). RRs ( $95 \% \mathrm{Cl}$ ) were 1.49 ( 1.30 to 1.72 ) and 2.20 ( 1.88 to 2.57 ) in former and current smokers for all deaths from cancer, and 1.24 ( 1.04 to 1.47 ) and 1.57 ( 1.28 to 1.94 ) for all cardiovascular deaths, respectively. Quitters had significantly lower risks of death than current smokers from all causes, lung cancer, all cancers, stroke and all cardiovascular diseases. Conclusions: In old age, smoking continues to be a major cause of death, and quitting is beneficial. Smoking cessation is urgently needed in rapidly ageing populations in the East.


Many Western prospective studies have shown that much of the all-cause mortality, including lung cancer, cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) are caused by cigarette smoking. ${ }^{1-3}$ Globally, tobacco-related deaths are rising, mainly because of increasing cigarette consumption in developing countries, especially China. ${ }^{4}$
Prospective studies of smoking and mortality in China are few, ${ }^{5-9}$ and evidence from elderly people, especially women, is sparse. Some Western studies have found a lower risk of mortality from smoking in old age than in middle age. ${ }^{10}{ }^{11}$ Prospective studies are needed to monitor the growing tobacco epidemic particularly in rapidly developing regions and rapidly ageing populations. However, these populations, including mainland Chinese, are mostly in the early stage of the epidemic, and prospective studies ${ }^{8}$ would underestimate the risks, especially in elderly smokers. In Hong Kong, with a largely ethnic Chinese population, tobacco consumption reached its peak about 20 years earlier than in mainland China, but about 20 years later than in developed Western countries, such as the US. ${ }^{12-14}$ Evidence from elderly Chinese in Hong Kong can forewarn what will happen to their counterparts in the rest of China and also in other developing Asian countries. Only two papers, one from a large community-based case-control study ${ }^{14}$ and the other from a small prospective study, ${ }^{15}$ have reported the association between smoking and mortality in elderly Chinese in Hong Kong. This prospective study examined the relationship of smoking with all-cause and major cause-specific mortality in elderly Chinese men and women, respectively, in Hong Kong.

## METHODS

## Sample

Since July 1998, 18 Elderly Health Centres have been established to provide health examination and primary care services by the Department of Health of the Government of the Hong Kong Special Administrative Region. All elderly people aged $\geqslant 65$ years were encouraged to enroll at a nominal fee, which was waived for the poor. All 56167 clients who first enrolled from July 1998 to December 2000 were included, almost all were community-dwelling older people and a minority lived in institutions ( $4.3 \%$ ). Details of the methods have been reported previously. ${ }^{16}{ }^{17}$ Smoking was defined as "at least one cigarette per day continuously for at least 1 year". Current smokers were people who had ever smoked and who were still smoking at baseline. Former smokers were ever smokers who had stopped smoking for at least l year. Never smokers were those who had never smoked at least one cigarette a day continuously for at least 1 year.

## Follow-up

Vital status and causes of death by 31 December 2003 were ascertained from official death registration, specialist outpatient and hospitalisation databases by linking the unique identity card number of every client. Failing these, the subjects were followed up by telephone interview from November 2004 to January 2005. This yielded a mean (SD) follow-up duration of 4.1 (0.9) years among 54216 subjects, with 1951 ( $3.5 \%$ ) lost

Abbreviations: COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease

Table 1 Baseline characteristics of 54214 clients in Elderly Health Centres in Hong Kong by sex and smoking status

| Characteristics | Men |  |  |  | Women |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Never smoker, n (\%) | Former smoker, n (\%) | Current smoker, n (\%) | $\chi^{2} \mathrm{p}$ Value | Never smoker, n (\%) | Former smoker, n (\%) | Current smoker, n (\%) | $\chi^{2} \mathrm{p}$ Value |
| Sex | 7072 (38.9) | 7455 (41.0) | 3635 (20.0) |  | 31767 (88.1) | 2853 (7.9) | 1432 (4.0) |  |
| Age (years) |  |  |  | $<0.001$ |  |  |  | $<0.001$ |
| 65-69 | 3043 (43.0) | 2520 (33.8) | 1497 (41.2) |  | 13127 (41.3) | 681 (23.9) | 463 (32.3) |  |
| 70-74 | 2156 (30.5) | 2487 (33.4) | 1218 (33.5) |  | 9595 (30.2) | 845 (29.6) | 479 (33.4) |  |
| 75-79 | 1164 (16.5) | 1561 (20.9) | 626 (17.2) |  | 5615 (17.7) | 726 (25.4) | 310 (21.6) |  |
| $\geqslant 80$ | 709 (10.0) | 887 (11.9) | 294 (8.1) |  | 3430 (10.8) | 601 (21.1) | 180 (12.6) |  |
| Education |  |  |  | $<0.001$ |  |  |  | $<0.001$ |
| Secondary or above | 2686 (38.0) | 1998 (26.8) | 809 (22.3) |  | 3239 (10.2) | 156 (5.5) | 92 (6.4) |  |
| Primary | 3377 (47.8) | 4053 (54.4) | 1988 (54.7) |  | 9358 (29.5) | 786 (27.5) | 370 (25.8) |  |
| No formal education but can read and write | 565 (8.0) | 840 (11.3) | 470 (12.9) |  | 6301 (19.8) | 657 (23) | 304 (21.2) |  |
| Illiterate | 444 (6.3) | 564 (7.6) | 389 (10.2) |  | 12869 (40.5) | 1254 (44) | 666 (46.5) |  |
| Ever alcoholic | 2175 (30.8) | 4667 (62.6) | 2119 (58.3) | $<0.001$ | 3747 (11.8) | 1038 (36.4) | 420 (29.3) | <0.001 |
| Regular exercise | 6064 (85.8) | 6344 (85.1) | 2696 (74.2) | <0.001 | 27346 (86.1) | 2427 (85.1) | 1066 (74.4) | $<0.001$ |
| Active chronic diseases |  |  |  |  |  |  |  |  |
| Hypertension | 2655 (37.5) | 2683 (36.0) | 920 (25.3) | $<0.001$ | 11995 (37.6) | 1050 (36.8) | 347 (24.2) | <0.001 |
| Diabetes mellitus | 928 (13.1) | 966 (13.0) | 341 (9.4) | <0.001 | 4078 (12.8) | 367 (12.9) | 127 (8.9) | $<0.001$ |
| Heart disease | 810 (11.5) | 1045 (14.0) | 299 (8.2) | $<0.001$ | 4156 (13.1) | 442 (15.5) | 150 (10.5) | $<0.001$ |
| COPD/asthma | 272 (3.8) | 842 (11.3) | 370 (10.2) | <0.001 | 1147 (3.6) | 362 (12.7) | 134 (9.4) | <0.001 |
| Hypercholesterolaemia | 892 (12.6) | 925 (12.4) | 313 (8.6) | $<0.001$ | 5763 (18.1) | 520 (18.2) | 162 (11.3) | $<0.001$ |
| Cerebrovascular accident | 243 (3.4) | 364 (4.9) | 116 (3.2) | <0.001 | 866 (2.7) | 88 (3.1) | 38 (2.7) | 0.520 |
| Medication taken regularly | 3776 (53.4) | 4287 (57.5) | 1529 (42.1) | <0.001 | 17228 (54.2) | 1676 (58.7) | 613 (42.8) | <0.001 |
| Any admission to hospital in the last year | 895 (12.7) | 1240 (16.6) | 451 (12.4) | $<0.001$ | 3965 (12.5) | 482 (16.9) | 156 (10.9) | <0.001 |
| Unintentional weight loss $\geqslant 10 \mathrm{lb}$ during the past 6 months | 170 (2.4) | 246 (3.3) | 120 (3.3) | 0.001 | 747 (2.4) | 110 (3.9) | 51 (3.6) | $<0.001$ |
| Monthly personal expenditure (US\$1 = HK\$7.814) |  |  |  | $<0.001$ |  |  |  | $<0.001$ |
| <HK\$1000 (£65, €96) | 834 (11.8) | 972 (13.0) | 378 (10.4) |  | 5357 (16.9) | 509 (17.8) | 282 (19.7) |  |
| $\begin{aligned} & \text { HK\$1000-1999 (£65-130, } \\ & \text { €96-192) } \end{aligned}$ | 2549 (36.0) | 2778 (37.3) | 1288 (35.4) |  | 12648 (39.8) | 1026 (36.0) | 505 (35.3) |  |
| HK\$ 2000 ( $£ 130, € 192$ ) | 3689 (52.2) | 3705 (49.7) | 1969 (54.2) |  | 13759 (43.3) | 1318 (46.2) | 645 (45.0) |  |
| Regular contact with relatives | 6869 (97.1) | 7204 (96.6) | 3466 (95.4) | <0.001 | 30979 (97.5) | 2726 (95.5) | 1379 (96.3) | $<0.001$ |
| BMI category ( $\mathrm{kg} / \mathrm{m}^{2}$ ) |  |  |  | $<0.001$ |  |  |  | $<0.001$ |
| $<18.5$ (underweight) | 325 (4.6) | 391 (5.3) | 345 (9.5) |  | 1438 (4.5) | 240 (8.4) | 222 (15.5) |  |
| 18.5-22.9 (normal weight) | 2178 (30.9) | 2371 (31.9) | 1526 (42.0) |  | 9635 (30.4) | 904 (31.8) | 529 (36.9) |  |
| 23.0-24.9 (at risk of obesity) | 1782 (25.2) | 1819 (24.5) | 733 (20.2) |  | 6971 (22.0) | 573 (20.1) | 265 (18.5) |  |
| 25.0-29.9 (obesity I) | 2480 (35.1) | 2556 (34.4) | 920 (25.3) |  | 11219 (35.4) | 947 (33.3) | 343 (24.0) |  |
| $\geqslant 30.0$ (obesity II) | 293 (4.2) | 300 (4) | 108 (3.0) |  | 2425 (7.7) | 180 (6.3) | 73 (5.1) |  |
| Self-rated health |  |  |  | <0.001 |  |  |  | $<0.001$ |
| Better | 2113 (29.9) | 2201 (29.5) | 1087 (29.9) |  | 6498 (20.5) | 664 (23.3) | 303 (21.2) |  |
| Normal | 4637 (65.6) | 4811 (64.5) | 2322 (63.9) |  | 22444 (70.7) | 1876 (65.8) | 1006 (70.3) |  |
| Worse | 321 (4.5) | 443 (5.9) | 226 (6.2) |  | 2822 (8.9) | 313 (11.0) | 123 (8.6) |  |
| Functional disability | 318 (4.5) | 473 (6.3) | 178 (4.9) | $<0.001$ | 2675 (8.4) | 367 (12.9) | 121 (8.4) | $<0.001$ |
| Depressive symptoms | 260 (3.7) | 370 (5.0) | 256 (7.0) | $<0.001$ | 2366 (7.5) | 309 (10.9) | 164 (11.5) | $<0.001$ |

BMI, body mass index; COPD, chronic obstructive pulmonary disease.
Subjects with missing data were excluded.
to follow-up. By the end of 2003, 50332 were still alive and 3884 deaths had occurred, 3829 of known causes and 55 of unknown causes. In addition to the 1951 subjects lost to followup, 2 subjects without a smoking status were also excluded, leaving 54214 older people and 3883 deaths ( 1848 men and 2035 women) for analysis. Causes of death obtained for 3829 subjects were routinely coded by the governmental Department of Health according to the International classification of diseases9th revision before 2001 and 10th revision in and after 2001.

## Statistical analysis

A Cox proportional hazards model was used to estimate the relative risks (RRs, or hazard ratio) and the $95 \%$ CIs of all-cause and cause-specific mortality by smoking status (never smoker as
the reference group), with adjustment for potential baseline confounders. The proportional hazards assumption was checked by visual inspection of plots of $\log (-\log (S))$ against time, where $S$ was the estimated survival function. For cause-specific mortality analyses, subjects who died of other causes or unknown causes were regarded as censored at the date of death. ${ }^{1819}$ The population-attributable risk percentage (for all the study subjects) for all-cause mortality was based on the formula ( $\mathrm{Pe}(\mathrm{RR}-1) / 1+\mathrm{Pe}$ (RR-1)), where Pe was the prevalence of ever smoking and RR the adjusted RR for all-cause mortality. All statistical analyses were performed using SPSS V.13.0. Ethical approval was obtained from the ethics committee of the Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong. The study complied with the principles of the Declaration of Helsinki.

Table 2 Crude mortality (per 100000 person-years) of 54214 clients in Elderly Health Centres in Hong Kong by sex and smoking status

| Cause of death | Never smoker |  | Current smoker (cigarettes per day) |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Former smoker |  | All current smoker |  | 1-9* |  | 10-20* |  | >20* |  |
|  | n | Mortality | n | Mortality | n | Mortality | n | Mortality | n | Mortality | n | Mortality |
| Men |  |  |  |  |  |  |  |  |  |  |  |  |
| Subjects | 7072 |  | 7455 |  | 3635 |  | 1391 |  | 1547 |  | 564 |  |
| Person-years | 29136 |  | 29856 |  | 14299 |  | 5557 |  | 6126 |  | 2018 |  |
| Malignant neoplasm |  |  |  |  |  |  |  |  |  |  |  |  |
| Lung cancer | 31 | 106 | 112 | 375 | 116 | 811 | 42 | 756 | 54 | 882 | 18 | 892 |
| All cancers | 179 | 614 | 321 | 1075 | 241 | 1685 | 92 | 1656 | 109 | 1779 | 34 | 1685 |
| Cardiovascular disease |  |  |  |  |  |  |  |  |  |  |  |  |
| Ischaemic heart disease | 67 | 230 | 83 | 278 | 40 | 280 | 15 | 270 | 19 | 310 | 6 | 297 |
| Stroke | 42 | 144 | 71 | 238 | 40 | 280 | 17 | 306 | 17 | 278 | 4 | 198 |
| All cardiovascular disease | 143 | 491 | 218 | 730 | 103 | 720 | 43 | 774 | 46 | 751 | 12 | 595 |
| Respiratory disease |  |  |  |  |  |  |  |  |  |  |  |  |
| COPD | 24 | 82 | 95 | 318 | 30 | 210 | 17 | 306 | 7 | 114 | 6 | 297 |
| All respiratory diseases $\dagger$ | 80 | 275 | 192 | 643 | 61 | 427 | 30 | 540 | 20 | 326 | 10 | 496 |
| All causes | 508 | 1744 | 869 | 2911 | 471 | 3294 | 202 | 3635 | 193 | 3151 | 66 | 3271 |
| Women |  |  |  |  |  |  |  |  |  |  |  |  |
| Subjects | 31767 |  | 2853 |  | 1432 |  | 892 |  | 374 |  | 78 |  |
| Person-years | 133270 |  | 11804 |  | 5910 |  | 3703 |  | 1513 |  | 298 |  |
| Malignant neoplasm |  |  |  |  |  |  |  |  |  |  |  |  |
| Lung cancer | 162 | 122 | 52 | 441 | 29 | 491 | 21 | 567 | 6 | 396 | 0 | 0 |
| All cancers | 615 | 461 | 101 | 856 | 52 | 880 | 35 | 945 | 13 | 859 | 0 | 0 |
| Cardiovascular disease |  |  |  |  |  |  |  |  |  |  |  |  |
| Ischaemic heart disease | 181 | 136 | 29 | 246 | 13 | 220 | 6 | 162 | 4 | 264 | 2 | 671 |
| Stroke | 183 | 137 | 32 | 271 | 13 | 220 | 8 | 216 | 2 | 132 | 2 | 671 |
| All cardiovascular disease | 484 | 363 | 81 | 686 | 33 | 558 | 20 | 540 | 6 | 396 | 4 | 1343 |
| Respiratory disease |  |  |  |  |  |  |  |  |  |  |  |  |
| COPD | 35 | 26 | 38 | 322 | 9 | 152 | 5 | 135 | 1 | 66 | 1 | 336 |
| All respiratory diseases $\dagger$ | 171 | 128 | 64 | 542 | 16 | 271 | 10 | 270 | 3 | 198 | 1 | 336 |
| All causes | 1622 | 1217 | 299 | 2533 | 114 | 1929 | 75 | 2025 | 24 | 1586 | 5 | 1678 |

COPD, chronic obstructive pulmonary disease.
*Subjects with missing data on cigarette consumption daily were excluded.
$\dagger$ Includes COPD, respiratory tuberculosis and other respiratory diseases.

## RESULTS

## Characteristics of subjects at baseline

We compared (a) the baseline data of age, education and smoking patterns in our cohort with the census and general population data, and (b) the proportionate mortality of major causes of deaths in our cohort with the Hong Kong Death Registry population data. More women than men enrolled in the study; however, for each sex the Cohen effect sizes ${ }^{20}$ were small, ${ }^{17}$ suggesting that even if our cohort, made up of volunteers, might be more health conscious, it should be reasonably representative of the general population of the same age in terms of basic demographic characteristics and mortality outcomes. The mean (SD) age of 18162 men and 36052 women at baseline were 72.8 (5.4) and 73.1 (5.8) years. There were more male than female current smokers ( $20.0 \%$ vs $4.0 \%$ ) and former smokers ( $41.0 \%$ vs $7.9 \%$; $\mathrm{p}<0.001$ ). Table 1 shows that there were more current smokers than never smokers who drank alcohol, did not exercise regularly, had unintentional weight loss in the past 6 months, rated their health as worse, had depressive symptoms and had lower body mass index in both sexes.

## Mortality by smoking status

Table 2 shows that in men and women, the mortality in former and current-smokers was higher than that in never smokers. Table 3 shows that in men, after adjusting for potential baseline confounders, current smokers and former smokers had significantly higher risks of death from lung cancer than never smokers (RR 6.66, 95\% CI 4.41 to 10.06; RR 3.30, $95 \%$ CI 2.19 to 4.98 ), all cancers (RR 2.52, 95\% CI 2.05 to 3.10; RR 1.65, 95\% CI 1.36 to 2.00) and all causes (RR $1.75,95 \%$ CI 1.53 to 2.00 ; RR $1.39,95 \%$ CI 1.23 to 1.56 ). Current smokers also had a significantly higher risk of death from stroke than never smokers (RR 2.07, 95\% CI 1.30 to 3.29) and all CVDs (RR 1.54, 95\% CI 1.18 to 2.02), but former smokers did not. Former smokers showed higher risks of death from COPD than never smokers (RR 1.72, 95\% CI 1.06 to 2.80) and all respiratory diseases (RR $1.39,95 \%$ CI 1.04 to 1.87 ), but current smokers did not. Significant positive linear trends were also found between increasing smoking status (from never smokers, former smokers and current smokers who consumed l-$9,10-20$ and $>20$ cigarettes daily) and risks of death from lung cancer, all cancers, stroke, all CVDs and all causes. Similar results were also found in women.

Table 3 Adjusted RR with $95 \% \mathrm{Cl}$ for all-cause and cause-specific death by smoking status of clients in Elderly Health Centres in Hong Kong

| Cause of deaths | Never smoker <br> RR | $\frac{\text { Former smoker }}{\text { RR (95\% CI) }}$ | $\frac{\text { All current smoker }}{\text { RR ( } 95 \% \text { CI) }}$ | Cigarette consumption per day for current smoker |  |  | Linear test for trend $1 \dagger$ | Linear test for trend $2 \ddagger$ | Ever smoker§ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | 1-9 | 10-20 | $>20$ |  |  |  |
|  |  |  |  | RR (95\% CI) | RR (95\% CI) | RR (95\% CI) | $p$ Value | p Value | RR (95\% CI) |
| Men* |  |  |  |  |  |  |  |  |  |
| Malignant neoplasm |  |  |  |  |  |  |  |  |  |
| Lung cancer | 1.00 | $\begin{aligned} & 3.30^{0 * * *}(2.19 \text { to } \\ & 4.98) \end{aligned}$ | $\begin{aligned} & 6.66^{* * *}(4.41 \text { to } \\ & 10.06) \end{aligned}$ | $\begin{aligned} & 6.07 * * *(3.77 \text { to } \\ & 9.77) \end{aligned}$ | $\begin{aligned} & 7.40^{* * * *}(4.67 \text { to } \\ & 11.73) \end{aligned}$ | $\begin{aligned} & 7.52^{* * *}(4.13 \text { to } \\ & 13.70) \end{aligned}$ | <0.001 | <0.001 | $\begin{aligned} & 4.42^{* * *}(3.00 \text { to } \\ & 6.51) \end{aligned}$ |
| All cancers | 1.00 | $\begin{aligned} & 1.65^{\text {te* }}(1.36 \text { to } \\ & 2.00) \end{aligned}$ | $\begin{aligned} & 2.52^{* * *}(2.05 \text { to } \\ & 3.10) \end{aligned}$ | $\begin{aligned} & 2.34^{* * * *}(1.81 \text { to } \\ & 3.04) \end{aligned}$ | $\begin{aligned} & 2.77^{* * *}(2.15 \text { to } \\ & 3.56) \end{aligned}$ | $\begin{aligned} & 2.58^{* * *} \text { ( } 1.76 \text { to } \\ & 3.78 \text { ) } \end{aligned}$ | <0.001 | <0.001 | $\begin{aligned} & 1.93^{* * *}(1.61 \text { to } \\ & 2.31) \end{aligned}$ |
| Cardiovascular disease |  |  |  |  |  |  |  |  |  |
| CHD | 1.00 | $\begin{aligned} & 0.89 \text { ( } 0.63 \text { to } \\ & 1.27 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.20 \text { ( } 0.79 \text { to } \\ & 1.83 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.10(0.62 \text { to } \\ & 1.96) \end{aligned}$ | $\begin{aligned} & 1.38 \text { ( } 0.81 \text { to } \\ & 2.37 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.47 \text { ( } 0.62 \text { to } \\ & 3.47 \text { ) } \end{aligned}$ | 0.51 | 0.19 | $\begin{aligned} & 0.98 \text { ( } 0.71 \text { to } \\ & 1.36 \text { ) } \end{aligned}$ |
| Stroke | 1.00 | $\begin{aligned} & 1.33 \text { (0.88 to } \\ & 2.02) \end{aligned}$ | $\begin{aligned} & 2.07^{* * *}(1.30 \text { to } \\ & 3.29) \end{aligned}$ | $\begin{aligned} & 1.98^{*}(1.10 \text { to } \\ & 3.55) \end{aligned}$ | $\begin{aligned} & 2.26^{* *} \text { ( } 1.25 \text { to } \\ & 4.09) \end{aligned}$ | $\begin{aligned} & 1.65 \text { ( } 0.58 \text { to } \\ & 4.73 \text { ) } \end{aligned}$ | 0.002 | 0.005 | $\begin{aligned} & 1.55^{*}(1.05 \text { to } \\ & 2.28) \end{aligned}$ |
| All | 1.00 | $\begin{aligned} & 1.20 \text { ( } 0.95 \text { to } \\ & 1.50 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.54^{* *} \text { (1.18 to } \\ & 2.02 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.52^{*}(1.07 \text { to } \\ & 2.16) \end{aligned}$ | $\begin{aligned} & 1.70^{* *}(1.20 \text { to } \\ & 2.41) \end{aligned}$ | $\begin{aligned} & 1.43 \text { (0.78 to } \\ & 2.62 \text { ) } \end{aligned}$ | 0.002 | 0.002 | $\begin{aligned} & 1.29^{*}(1.04 \text { to } \\ & 1.60) \end{aligned}$ |
| Respiratory disease |  |  |  |  |  |  |  |  |  |
| COPD | 1.00 | $\begin{aligned} & 1.72^{*}(1.06 \text { to } \\ & 2.80 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.19 \text { ( } 0.67 \text { to } \\ & 2.14 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.53(0.78 \text { to } \\ & 2.98) \end{aligned}$ | $\begin{aligned} & 0.67 \text { (0.28 to } \\ & 1.62) \end{aligned}$ | $\begin{aligned} & 2.24(0.89 \text { to } \\ & 5.68) \end{aligned}$ | 0.68 | 0.94 | $\begin{aligned} & 1.56(0.97 \text { to } \\ & 2.51) \end{aligned}$ |
| All | 1.00 | $\begin{aligned} & 1.39^{*}(1.04 \text { to } \\ & 1.87) \end{aligned}$ | $\begin{aligned} & 1.12 \text { (0.78 to } \\ & 1.61 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.21 \text { ( } 0.77 \text { to } \\ & 1.88 \text { ) } \end{aligned}$ | $\begin{aligned} & 0.93 \text { ( } 0.56 \text { to } \\ & 1.55 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.52 \text { ( } 0.77 \text { to } \\ & 3.00 \text { ) } \end{aligned}$ | 0.47 | 0.68 | $\begin{aligned} & 1.31 \text { ( } 0.99 \text { to } \\ & 1.74 \text { ) } \end{aligned}$ |
| All causes | 1.00 | $\begin{aligned} & 1.39 \text { *** ( } 1.23 \text { to } \\ & 1.56 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.75^{* * *}(1.53 \text { to } \\ & 2.00) \end{aligned}$ | $\begin{aligned} & 1.01 \\ & 1.75^{\text {+ex }}(1.47 \text { to } \\ & 2.07) \end{aligned}$ | $\begin{aligned} & 1.78^{* * *} \text { ( } 1.50 \text { to } \\ & 2.12 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.87^{* * *} \text { (1.44 to } \\ & 2.45 \text { ) } \end{aligned}$ | <0.001 | <0.001 | $\begin{aligned} & 1.50^{* * *}(1.34 \text { to } \\ & 1.67) \end{aligned}$ |
| Woment |  |  |  |  |  |  |  |  |  |
| Malignant neoplasm |  |  |  |  |  |  |  |  |  |
| Lung cancer | 1.00 | $\begin{aligned} & 2.74^{* * *}(1.95 \text { to } \\ & 3.83) \end{aligned}$ | $\begin{aligned} & 3.19^{* * *}(2.11 \text { to } \\ & 4.83) \end{aligned}$ | $\begin{aligned} & 3.44^{* * *}(2.14 \text { to } \\ & 5.52) \end{aligned}$ | $\begin{aligned} & 2.85 *(1.25 \text { to } \\ & 6.51) \end{aligned}$ | Undetermined | <0.001 | <0.001 | $\begin{aligned} & 2.89 * * * \\ & 3.86 \text { ) } \end{aligned}$ |
| All cancers | 1.00 | $\begin{aligned} & 1.42 * *(1.14 \text { to } \\ & 1.78) \end{aligned}$ | $\begin{aligned} & 1.66^{* *} \text { ( } 1.24 \text { to } \\ & 2.23 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.68^{* *}(1.18 \text { to } \\ & 2.38) \end{aligned}$ | $\begin{aligned} & 1.79 *(1.03 \text { to } \\ & 3.12) \end{aligned}$ | Undetermined | <0.001 | <0.001 | $\begin{aligned} & 1.50^{* * *}(1.24 \text { to } \\ & 1.81) \end{aligned}$ |
| Cardiovascular disease |  |  |  |  |  |  |  |  |  |
| CHD | 1.00 | $\begin{aligned} & 1.20(0.79 \text { to } \\ & 1.83) \end{aligned}$ | $\begin{aligned} & 1.58 \text { ( } 0.89 \text { to } \\ & 2.81 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.04 \text { ( } 0.46 \text { to } \\ & 2.38 \text { ) } \end{aligned}$ | $\begin{aligned} & 2.44 \text { ( } 0.90 \text { to } \\ & 6.64 \text { ) } \end{aligned}$ | $\begin{aligned} & 6.64^{*} \text { ( } 1.62 \text { to } \\ & 27.17 \end{aligned}$ | 0.096 | 0.029 | $\begin{aligned} & 1.30(0.91 \text { to } \\ & 1.87) \end{aligned}$ |
| Stroke | 1.00 | $\begin{aligned} & 1.31 \text { ( } 0.87 \text { to } \\ & 1.99 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.60(0.90 \text { to } \\ & 2.86) \end{aligned}$ | $\begin{aligned} & 1.41 \text { ( } 0.69 \text { to } \\ & 2.91 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.17 \text { ( } 0.29 \text { to } \\ & 474 \text { ) } \end{aligned}$ | $\begin{aligned} & 6.87 * * ~(1.68 \text { to } \\ & 28.06 \end{aligned}$ | 0.054 | 0.033 | $\begin{aligned} & 1.39 \text { ( } 0.97 \text { to } \\ & 1.99 \text { ) } \end{aligned}$ |
| All | 1.00 | $\begin{aligned} & 1.28 \text { (0.99 to } \\ & 1.66 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.56^{*}(1.09 \text { to } \\ & 2.24) \end{aligned}$ | $\begin{aligned} & 1.36(0.86 \text { to } \\ & 2.14) \end{aligned}$ | $\begin{aligned} & 1.37(0.61 \text { to } \\ & 3.09) \end{aligned}$ | $\begin{aligned} & 5.07 * * \text { (1.88 to } \\ & 13.68 \end{aligned}$ | 0.004 | 0.002 | $\begin{aligned} & 1.36^{* *}(1.09 \text { to } \\ & 1.70) \end{aligned}$ |
| Respiratory disease |  |  |  |  |  |  |  |  |  |
| COPD | 1.00 | $\begin{aligned} & 3.84^{* * *}(2.26 \text { to } \\ & 6.51) \end{aligned}$ | $\begin{aligned} & 2.37^{*}(1.07 \text { to } \\ & 5.24) \end{aligned}$ | $\begin{aligned} & 1.78 \text { (0.66 to } \\ & 4.82 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.16 \text { ( } 0.15 \text { to } \\ & 8.83 \text { ) } \end{aligned}$ | $\begin{aligned} & 7.92(1.00 \text { to } \\ & 62.75) \end{aligned}$ | <0.001 | 0.002 | $\begin{aligned} & 3.41^{* * *}(2.06 \text { to } \\ & 5.63) \end{aligned}$ |
| All respiratory diseases | 1.00 | $\begin{aligned} & 2.07 * * * \\ & 2.88) \end{aligned}$ | $\begin{aligned} & 1.39(0.80 \text { to } \\ & 2.41) \end{aligned}$ | $\begin{aligned} & 1.14 \text { ( } 0.57 \text { to } \\ & 2.29 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.38 \text { (0.43 to } \\ & 4.37 \text { ) } \end{aligned}$ | $\begin{aligned} & 3.33 \text { ( } 0.46 \text { to } \\ & 24.24 \text { ) } \end{aligned}$ | 0.002 | 0.005 | $\begin{aligned} & 1.87^{* * *} \text { ( } 1.38 \text { to } \\ & 2.54 \text { ) } \end{aligned}$ |
| All causes | 1.00 | $\begin{aligned} & 1.43^{* * *}(1.25 \text { to } \\ & 1.64) \end{aligned}$ | $\begin{aligned} & 1.38^{* *} \text { ( } 1.14 \text { to } \\ & 1.68 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.31 *(1.04 \text { to } \\ & 1.67) \end{aligned}$ | $\begin{aligned} & 1.37(0.91 \text { to } \\ & 2.05) \end{aligned}$ | $\begin{aligned} & 1.59 \text { ( } 0.66 \text { to } \\ & 3.85 \text { ) } \end{aligned}$ | <0.001 | <0.001 | $\begin{aligned} & 1.42^{\star * *}(1.26 \text { to } \\ & 1.59) \end{aligned}$ |

[^0]
## Effects of quitting on mortality

For men, former smokers had significantly lower risks of death from lung cancer (RR 0.51, 95\% CI 0.39 to 0.67 ), all cancers (RR $0.64,95 \%$ CI 0.54 to 0.77 ), stroke (RR $0.63,95 \%$ CI 0.41 to 0.95 ) and all causes (RR $0.81,95 \%$ CI 0.72 to 0.91 ) than current smokers. For women, quitting also reduced risks of mortality from lung cancer, all cancers, ischaemic heart disease, stroke and all CVDs, although the differences were not significant (table 4). However, higher risks of death from COPD were found in former smokers in men and women.

## Excluding those who died soon after their first enrolment

When the analyses were repeated after excluding 244 deaths within 6 months of their first enrolment to reduce the "ill quitter effect" or "healthy smoker effect", similar results were observed; but the risks of death from COPD (RR 1.43, 95\% CI 0.97 to 2.12 ) and all respiratory diseases (RR 1.30, $95 \%$ CI 0.99 to 1.72 ) in former smokers became insignificant (tables 5 and $6)$.

## Population-attributable risk percentage for all-cause mortality

Table 3 shows that male and female ever smokers (combining current and former smokers) had $50 \%$ and $42 \%$ higher risks of all-cause death, respectively. The population-attributable fractions for all-cause mortality were $23.4 \%$ ( $95 \%$ CI $22.8 \%$ to $24.0 \%$ ) for men and $4.8 \%$ ( $95 \%$ CI $4.5 \%$ to $5.0 \%$ ) for women.

## DISCUSSION

Most prospective studies on smoking and mortality are on middle-aged subjects, and have clearly shown that smoking is associated with increased risks of all-cause mortality and causespecific mortality from CVDs, cancer and respiratory diseases, including the American Cancer Society Cancer Prevention Study 2 data used to estimate deaths attributable to smoking in the US. ${ }^{21}$ Far fewer studies have focused on older people, especially older women, and the results are inconsistent. Some found that the effects of smoking on mortality in elderly people were similar to those in middle-aged people, ${ }^{2223}$ but others showed no statistically or only marginally significantly

Table 4 Adjusted RR ( $95 \% \mathrm{Cl}$ ) for all-cause mortality and cause-specific mortality for quitting from smoking (former smokers compared with current smokers) of clients in Elderly Health Centres in Hong Kong

| Cause of death | Men $\dagger$ $\text { RR ( } 95 \% \mathrm{Cl})$ | Women $\dagger$ RR ( $95 \% \mathrm{Cl}$ ) | Total $\ddagger$ <br> RR ( $95 \% \mathrm{Cl}$ ) |
| :---: | :---: | :---: | :---: |
| Malignant neoplasm |  |  |  |
| Lung cancer | 0.51 *** (0.39 to 0.67) | 0.86 (0.53 to 1.41) | $0.58 * * *(0.46$ to 0.73$)$ |
| All cancers | $0.64 * * *(0.54$ to 0.77$)$ | 0.89 (0.63 to 1.28) | $0.69{ }^{* * *}$ ( 0.59 to 0.80 ) |
| Cardiovascular disease |  |  |  |
| Ischaemic heart disease | 0.75 (0.50 to 1.12) | 0.81 (0.40 to 1.63) | 0.77 (0.54 to 1.09) |
| Stroke | $0.63 *(0.41$ to 0.95) | 0.68 (0.33 to 1.38) | $0.67 *$ ( 0.47 to 0.95) |
| All cardiovascular | 0.78 (0.61 to 1.00) | 0.8 (0.52 to 1.23) | $0.79 *$ (0.64 to 0.98) |
| Respiratory disease |  |  |  |
| COPD | 1.42 (0.91 to 2.22) | 1.86 (0.85 to 4.07) | 1.49* (1.02 to 2.18) |
| All respiratory | 1.22 (0.90 to 1.66 ) | 1.68 (0.91 to 3.08) | $1.32 *$ (1.01 to 1.73) |
| All causes | $0.79 * * *(0.70$ to 0.89$)$ | 1.04 (0.82 to 1.31) | $0.84 * *(0.75$ to 0.93 ) |

* $p<0.05,{ }^{* *} p<0.01,{ }^{* * *} p<0.001$.
$\dagger$ Adjusted for age, education, alcohol consumption, physical exercise and active chronic diseases: hypertension, diabetes mellitus, heart disease, chronic obstructive pulmonary disease/asthma, hypercholesterolaemia, cerebrovascular accident, regular medication, admission to hospital, monthly personal expenditure, regular contact with relatives, unintentional weight loss in the past 6 months, body mass index, self-rated health, functional disability and depressive symptoms.
$\ddagger$ Adjusted for sex and the variables above.
increased risks of mortality. ${ }^{1024}$ The results for former smokers are more controversial. Some studies combined former smokers with current smokers, and few potentially confounding variables were adjusted for. Some studies suggest that even among elderly people, the effects of smoking on mortality may differ between younger-old and older-old people. ${ }^{10}{ }^{11}$ The questions above need to be clarified in Western countries and also in developing countries, where populations are ageing rapidly and smoking has become more popular, especially in China, in which $30 \%$ of the world's cigarettes are consumed. ${ }^{25}{ }^{26}$ In mainland China, only one prospective study reported the detrimental effect of smoking on mortality in 1268 retired men in Xi'an. ${ }^{9}$ At present, the epidemic of smoking-related mortality in China is still in its early stages. Prospective evidence from Hong Kong, which is at a fairly advanced stage of an epidemic of tobacco deaths, can forewarn the growing epidemic in mainland China and Asia in the next few decades and support early intervention.
The present study consistently shows that both current and former smoking significantly increased the risks of all-cause death with dose-response relationships by daily cigarette consumption for both male and female older Chinese in Hong Kong. The RRs for current smokers were about 1.8 in men and 1.4 in women, which were slightly lower than those from Western countries, but higher than those previously reported from mainland China. LaCroix et al ${ }^{10}$ and Paganini-Hill and $\mathrm{Hsu}^{23}$ reported an RR of about 2.0 for older men in the US, whereas Vogt et al ${ }^{11}$ reported an RR of about 1.7-2.2 for older women. The prospective study from Xi'an by Lam et al ${ }^{9}$ revealed an RR of 1.5 for older men. However, the only previous Hong Kong elderly cohort study by Ho et al ${ }^{15}$ did not find statistically significantly increased risks of all-cause death for both male and female current smokers, but the sample size ( 999 men and 1033 women) was small and the duration of follow-up (3 years) was short.
Our elderly former smokers also showed increased RRs of 1.4 for all-cause mortality in both sexes ( $\mathrm{p}<0.001$ ). LaCroix et al ${ }^{10}$ found a similar RR of 1.5 in male quitters, but the RR was insignificant in women. Paganini-Hill and $\mathrm{Hsu}^{23}$ found lower risks than ours, with significant RRs of 1.2 in both male and female former smokers. Although Lam et al ${ }^{9}$ did not find a significantly higher risk of mortality in male former smokers in

Xi'an, China, they found similar results for ever smokers aged $\geqslant 70$ years in a large case-control study in Hong Kong, with odds ratios of 1.4 in men and 1.7 in women. ${ }^{14}$ It should be noted that the comparison of RRs of studies with different age distributions could be problematic if RR varies by age.
We found significantly higher risks for all cancers and lung cancer in current smokers and also in former smokers, while most other elderly cohort studies only found the risks in current smokers but not in former smokers. ${ }^{9-11} 1522$
Although smoking can cause ischaemic heart disease and CVDs, whether and to what extent the effects extend to those who have survived to old age need to be further examined. The Framingham Heart Study, with 30 years of follow-up, reported that there was no significant relationship between cigarette smoking and the incidence of and mortality from ischaemic heart disease, ${ }^{2427}$ although the American Cancer Society Cancer Prevention Study 2 did find increased mortality from ischaemic heart disease in both younger and older smokers. ${ }^{21}$ For men and women separately, we did not find any statistically significant association between smoking (both current smoking and former smoking) and mortality from ischaemic heart disease. But for female current smokers who consumed $>20$ cigarettes daily, we found a significantly increased risk, with a significant linear trend. Combining men and women, we found a significant linear trend between smoking and risk of mortality from ischaemic heart disease. If ischaemic heart disease tends to kill Chinese smokers at a younger age than other diseases, the excess risks from smoking in elderly Chinese people would be much lower because of a survivor effect.

Our male current smokers also showed a higher risk of death from stroke, which was consistent with studies from the West ${ }^{212829}$, whereas previous studies on Chinese did not find such a relationship. ${ }^{5-7}{ }^{14}$ This was also true for our female heavy smokers who smoked $>20$ cigarettes daily. We also found that only current smoking, but not former smoking, increased the risk of death from all CVDs for both men and women, with dose-response relationships. Further studies are needed in different countries on how interactions of smoking with different cultures and lifestyles affect stroke and heart disease in middle age and in old age.
Our finding of higher risks of mortality from COPD in former smokers than in current smokers is consistent with other

Table 5 Adjusted RR with $95 \% \mathrm{Cl}$ for all-cause and cause-specific death by smoking status of clients in Elderly Health Centres in Hong Kong after excluding 244 deaths, people who died within 6 months after their first enrolment

| Cause of deaths | Never smoker | Former smoker | All current smoker | Cigarette consumption per day for current smoker |  |  | Linear test for trend $1 \dagger$ | Linear test for trend $2 \ddagger$ | Ever smoker§ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | 1-9 | 10-20 | $>20$ |  |  |  |
|  | RR | RR (95\% CI) | RR (95\% CII) | RR (95\% CI) | RR (95\% CI) | RR (95\% CI) | $p$ Value | $p$ Value | RR (95\% CI) |
| Men ${ }^{\text {a }}$ |  |  |  |  |  |  |  |  |  |
| Malignant neoplasm |  |  |  |  |  |  |  |  |  |
| Lung cancer | 1.00 | $\begin{aligned} & 3.36^{* * *}(2.20 \text { to } \\ & 5.13) \end{aligned}$ | $\begin{aligned} & 6.65^{* * * *}(4.34 \text { to } \\ & 10.18) \end{aligned}$ | $\begin{aligned} & 6.17^{* * *}(3.78 \text { to } \\ & 10.07) \end{aligned}$ | $\begin{aligned} & 7.35^{* * *}(4.56 \text { to } \\ & 11.83) \end{aligned}$ | $\begin{aligned} & 7.24^{* * *}(3.86 \text { to } \\ & 13.59) \end{aligned}$ | <0.001 | <0.001 | $\begin{aligned} & 4.45^{* * *}(2.98 \text { to } \\ & 6.64) \end{aligned}$ |
| All cancers | 1.00 | $\begin{aligned} & 1.65^{* * * *}(1.35 \text { to } \\ & 2.01) \end{aligned}$ | $\begin{aligned} & 2.48^{* * * *}(2.00 \text { to } \\ & 3.07) \end{aligned}$ | $\begin{aligned} & 2.35^{* * * *}(1.79 \text { to } \\ & 3.07) \end{aligned}$ | $\begin{aligned} & 2.66^{* * *}(2.05 \text { to } \\ & 3.46) \end{aligned}$ | $\begin{aligned} & 2.57^{* * * *}(1.72 \text { to } \\ & 3.83) \end{aligned}$ | <0.001 | <0.001 | $\begin{aligned} & 1.92+* * * \\ & 2.30) \end{aligned}$ |
| Cardiovascular disease |  |  |  |  |  |  |  |  |  |
| CHD | 1.00 | $\begin{aligned} & 0.88 \text { ( } 0.62 \text { to } \\ & 1.27 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.17 \text { ( } 0.75 \text { to } \\ & 1.80 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.01(0.55 \text { to } \\ & 1.86 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.37 \text { (0.79 to } \\ & 2.38 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.54 \text { ( } 0.65 \text { to } \\ & 3.66 \text { ) } \end{aligned}$ | 0.624 | 0.223 | $\begin{aligned} & 0.96 \text { ( } 0.69 \text { to } \\ & 1.35 \text { ) } \end{aligned}$ |
| Stroke | 1.00 | $\begin{aligned} & 1.59^{*}(1.01 \text { to } \\ & 2.50) \end{aligned}$ | $\begin{aligned} & 2.56^{* * *}(1.56 \text { to } \\ & 4.22) \end{aligned}$ | $\begin{aligned} & 2.26^{*}(1.20 \text { to } \\ & 4.24) \end{aligned}$ | $\begin{aligned} & 2.99^{* *}(1.61 \text { to } \\ & 5.54) \end{aligned}$ | $\begin{aligned} & 2.22 \text { ( } 0.76 \text { to } \\ & 6.48 \text { ) } \end{aligned}$ | <0.001 | <0.001 | $\begin{aligned} & 1.87^{* *}(1.22 \text { to } \\ & 2.85) \end{aligned}$ |
| All | 1.00 | $\begin{aligned} & 1.26 \text { (0.99 to } \\ & 1.60 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.60^{* *}(1.20 \text { to } \\ & 2.12) \end{aligned}$ | $\begin{aligned} & 1.47^{*}(1.01 \text { to } \\ & 2.14) \end{aligned}$ | $\begin{aligned} & 1.87^{* *}(1.31 \text { to } \\ & 2.68) \end{aligned}$ | $\begin{aligned} & 1.49 \text { (0.79 to } \\ & 2.80 \text { ) } \end{aligned}$ | 0.001 | 0.001 | $\begin{aligned} & 1.35^{* *}(1.08 \text { to } \\ & 1.70) \end{aligned}$ |
| Respiratory disease |  |  |  |  |  |  |  |  |  |
| COPD | 1.00 | $\begin{aligned} & 1.78^{*} \text { (1.08 to } \\ & 2.96 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.24(0.68 \text { to } \\ & 2.26 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.53 \text { ( } 0.76 \text { to } \\ & 3.06 \text { ) } \end{aligned}$ | $\begin{aligned} & 0.73 \text { (0.30 to } \\ & 1.77 \text { ) } \end{aligned}$ | $\begin{aligned} & 2.41(0.94 \text { to } \\ & 6.16) \end{aligned}$ | 0.629 | 0.832 | $\begin{aligned} & 1.61 \text { ( } 0.98 \text { to } \\ & 2.65 \text { ) } \end{aligned}$ |
| All | 1.00 | $\begin{aligned} & 1.38^{*}(1.02 \text { to } \\ & 1.86) \end{aligned}$ | $\begin{aligned} & 1.12(0.77 \text { to } \\ & 1.61) \end{aligned}$ | $\begin{aligned} & 1.16 \text { (0.73 to } \\ & 1.83 \text { ) } \end{aligned}$ | $\begin{aligned} & 0.95 \text { ( } 0.57 \text { to } \\ & 1.60 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.59 \text { (0.80 to } \\ & 3.13 \text { ) } \end{aligned}$ | 0.495 | 0.633 | $\begin{aligned} & 1.30 \text { ( } 0.98 \text { to } \\ & 1.74 \text { ) } \end{aligned}$ |
| All causes | 1.00 | $\begin{aligned} & 1.40^{+* * *}(1.24 \text { to } \\ & 1.58) \end{aligned}$ | $\begin{aligned} & 1.75^{\text {**** }}(1.52 \text { to } \\ & 2.01) \end{aligned}$ | $\begin{aligned} & 1.74^{* * *}(1.46 \text { to } \\ & 2.07) \end{aligned}$ | $\begin{aligned} & 1.80^{* * * *}(1.50 \text { to } \\ & 2.16) \end{aligned}$ | $\begin{aligned} & 1.86^{* * *}(1.41 \text { to } \\ & 2.45) \end{aligned}$ | <0.001 | <0.001 | $\begin{aligned} & 1.51^{1 \times * *}(1.34 \text { to } \\ & 1.69) \end{aligned}$ |
| Women* |  |  |  |  |  |  |  |  |  |
| Malignant neoplasm |  |  |  |  |  |  |  |  |  |
| Lung cancer | 1.00 | $\begin{aligned} & 2.77^{* * *}(1.95 \text { to } \\ & 3.92) \end{aligned}$ | $\begin{aligned} & 3.25^{* * *}(2.11 \text { to } \\ & 4.99) \end{aligned}$ | $\begin{aligned} & 3.40^{* * * *}(2.07 \text { to } \\ & 5.59) \end{aligned}$ | $\begin{aligned} & 3.11^{* *}(1.36 \text { to } \\ & 7.12) \end{aligned}$ | Undetermined | <0.001 | <0.001 | $\begin{aligned} & 2.93^{* * * *}(2.17 \text { to } \\ & 3.95) \end{aligned}$ |
| All cancers | 1.00 | $\begin{aligned} & 1.46^{* *}(1.16 \text { to } \\ & 1.84) \end{aligned}$ | $\begin{aligned} & 1.73^{\text {**** }}(1.28 \text { to } \\ & 2.33) \end{aligned}$ | $\begin{aligned} & 1.69^{* *}(1.17 \text { to } \\ & 2.43) \end{aligned}$ | $\begin{aligned} & 1.98^{*} \text { (1.13 to } \\ & 3.45) \end{aligned}$ | Undetermined | <0.001 | <0.001 | $\begin{aligned} & 1.54^{* * *}(1.27 \text { to } \\ & 1.88 \text { ) } \end{aligned}$ |
| Cardiovascular disease |  |  |  |  |  |  |  |  |  |
| CHD | 1.00 | $\begin{aligned} & 1.30 \text { ( } 0.85 \text { to } \\ & 2.00 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.47 \text { (0.79 to } \\ & 2.74 \text { ) } \end{aligned}$ | $\begin{aligned} & 0.95 \text { ( } 0.39 \text { to } \\ & 2.34 \text { ) } \end{aligned}$ | $\begin{aligned} & 2.00 \text { ( } 0.63 \text { to } \\ & 6.33 \text { ) } \end{aligned}$ | $\begin{aligned} & 7.30^{* * *}(1.78 \text { to } \\ & 29.97) \end{aligned}$ | 0.112 | 0.043 | $\begin{aligned} & 1.35 \text { (0.93 to } \\ & 1.96 \text { ) } \end{aligned}$ |
| Stroke | 1.00 | $\begin{aligned} & 1.39 \text { (0.91 to } \\ & 2.12 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.46 \text { ( } 0.78 \text { to } \\ & 2.73 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.13 \text { ( } 0.50 \text { to } \\ & 2.60 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.26 \text { ( } 0.31 \text { to } \\ & 5.13 \text { ) } \end{aligned}$ | $\begin{aligned} & 7.73^{* *}(1.89 \text { to } \\ & 31.66) \end{aligned}$ | 0.084 | 0.047 | $\begin{aligned} & 1.41 \text { ( } 0.97 \text { to } \\ & 2.05 \text { ) } \end{aligned}$ |
| All | 1.00 | $\begin{aligned} & 1.37^{*}(1.05 \text { to } \\ & 1.78 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.48^{*} \text { (1.01 to } \\ & 2.18 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.24 \text { ( } 0.76 \text { to } \\ & 2.04 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.23(0.51 \text { to } \\ & 2.99) \end{aligned}$ | $\begin{aligned} & 5.62^{* *}(2.08 \text { to } \\ & 15.16) \end{aligned}$ | 0.005 | 0.003 | $\begin{aligned} & 1.40^{* *}(1.11 \text { to } \\ & 1.76) \end{aligned}$ |
| Respiratory disease |  |  |  |  |  |  |  |  |  |
| COPD | 1.00 | $\begin{aligned} & 3.72^{* * *}(2.14 \text { to } \\ & 6.45) \end{aligned}$ | $\begin{aligned} & 2.54^{*}(1.14 \text { to } \\ & 5.66) \end{aligned}$ | $\begin{aligned} & 1.92 \text { ( } 0.70 \text { to } \\ & 5.23 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.21 \text { ( } 0.16 \text { to } \\ & 9.20 \text { ) } \end{aligned}$ | $\begin{aligned} & 8.51 *(1.07 \text { to } \\ & 67.83) \end{aligned}$ | <0.001 | 0.002 | $\begin{aligned} & 3.37^{* * * *}(2.00 \text { to } \\ & 5.66) \end{aligned}$ |
| All | 1.00 | $\begin{aligned} & 2.08^{* * *}(1.48 \text { to } \\ & 2.93) \end{aligned}$ | $\begin{aligned} & 1.42(0.80 \text { to } \\ & 2.52) \end{aligned}$ | $\begin{aligned} & 1.36 \text { ( } 0.63 \text { to } \\ & 2.52 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.01 \text { ( } 0.25 \text { to } \\ & 4.111 \text { ) } \end{aligned}$ | $3.58 \text { (0. } 49 \text { to }$ | 0.002 | 0.008 | $\begin{aligned} & 1.89^{* * *}(1.38 \text { to } \\ & 2.60) \end{aligned}$ |
| All causes | 1.00 | $\begin{aligned} & 1.46^{* * * *}(1.27 \text { to } \\ & 1.67) \end{aligned}$ | $\begin{aligned} & 1.37^{* *} \text { (1.12 to } \\ & 1.68 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.28 \text { (1.00 to } \\ & 1.65) \end{aligned}$ | $\begin{aligned} & 1.36 \text { ( } 0.89 \text { to } \\ & 2.07 \text { ) } \end{aligned}$ | $\begin{aligned} & 1.74 \text { ( } 0.72 \text { to } \\ & 4.20 \text { ) } \end{aligned}$ | <0.001 | <0.001 | $\begin{aligned} & 1.43^{* * * *}(1.27 \text { to } \\ & 1.62) \end{aligned}$ |

CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease.
${ }^{*} p<0.05,{ }^{* *} p<0.01$, *** $p<0.001$.
†Linear trend with increasing smoking status from never to former and current smoker.
$\ddagger$ Linear trend with increasing smoking status from never smoker, former smoker and current smoker consuming 1-9, 10-20, and 21 cigarettes or more daily.
§Combining current smoker and former smoker.
-Adjusted for age, education, alcohol consumption, physical exercise, active chronic diseases: hypertension, diabetes mellitus, heart diseases, COPD/asthma, hypercholesterolaemia, cerebrovascular accident, regular medication, admission to hospital, monthly expenditure, regular contact with relatives, unintentional weight loss in the past 6 months, body mass index, self-rated health, functional disability and depressive symptoms.
findings. ${ }^{930}$ Female but not male current smokers also showed higher risks of death from COPD than never smokers, which was also consistent with studies from Lam et al ${ }^{9}$ and Vogt et al. ${ }^{11}$ Some authors explained this by either the healthy smoker effect or the ill quitter effect, or both, because older smokers were survivors with probably less serious disease and those susceptible to COPD would have died earlier. ${ }^{9}$ To reduce bias due to reverse causality, we carried out further analyses after excluding those who had died soon after their first enrolmentthat is, within 6 months-and the excess risks of death from COPD and all respiratory diseases in former smokers, compared with current smokers, became insignificant. Some have suggested that a reduction in the risk of mortality from COPD was observed only in those who had quit smoking for $>10$ years, ${ }^{30}$ but we could not examine the effect of years of quitting as data were not available.
We found significant effects of quitting; male former smokers had lower risks of mortality from all causes, lung
cancer, all cancers and stroke than current smokers. Similar patterns were also found in women, although the reduced risks were not statistically significant, probably because of the small number of deaths. In short, all the available evidence, including ours, has consistently shown substantial benefits of quitting smoking even in elderly people, confirming that quitting is not too late, even after the age of 65 .

One limitation of our study is that the period of follow-up was relatively short, but the number of deaths was enough to test some important hypotheses. In China and other developing countries where knowledge about the hazards of smoking is low, there is a common misbelief that smoking among elderly people is not that harmful (which is apparently supported by lower RRs due to a survivor effect) and that quitting may cause more harm (possibly due to reverse causality), particularly for COPD, which is a more common cause of death in China than in the West. ${ }^{89}$ Our results support the development of a strong smoking cessation policy. Volunteer bias is another possible

Table 6 Adjusted RR* $(95 \% \mathrm{CI})$ for all-cause mortality and cause-specific mortality for quitting from smoking (former smokers compared with current smokers) of clients in Elderly Health Centres in Hong Kong after excluding 244 deaths, people who died within 6 months after the first enrolment

|  | Ment | Woment | Total $\ddagger$ |
| :---: | :---: | :---: | :---: |
| Cause of death | RR (95\% CI) | RR (95\% CI) | RR (95\% CI) |
| Malignant neoplasm |  |  |  |
| Lung cancer | $0.52^{* * *}(0.39$ to 0.69$)$ | 0.87 (0.53 to 1.45) | $0.58 * * *(0.46$ to 0.75$)$ |
| All cancers | 0.66 *** (0.55 to 0.79) | 0.91 (0.63 to 1.31) | 0.70 *** (0.59 to 0.82) |
| Cardiovascular disease |  |  |  |
| Ischaemic heart disease | 0.77 (0.50 to 1.17) | 1.00 (0.48 to 2.11) | 0.82 (0.57 to 1.18) |
| Stroke | 0.61 * (0.39 to 0.93) | 0.80 (0.38 to 1.70) | $0.68 *(0.47$ to 0.98) |
| All cardiovascular disease | 0.79 (0.61 to 1.03) | 0.91 (0.58 to 1.43) | 0.82 (0.66 to 1.03) |
| Respiratory disease |  |  |  |
| COPD | 1.42 (0.90 to 2.24) | 1.65 (0.74 to 3.69) | 1.43 (0.97 to 2.12) |
| All respiratory | 1.21 (0.88 to 1.66) | 1.66 (0.88 to 3.12) | 1.30 (0.99 to 1.72) |
| All causes | 0.80 *** (0.71 to 0.90) | 1.08 (0.85 to 1.37) | $0.85 * *$ (0.76 to 0.95) |

${ }^{*} p<0.05,{ }^{* *} p<0.01,{ }^{* * *} p<0.001$.
†Adjusted for age, education, alcohol consumption, physical exercise, active chronic diseases: hypertension, diabetes mellitus, heart disease, COPD/asthma, hypercholesterolaemia, cerebrovascular accident, regular medication, admission to hospital, monthly personal expenditure, regular contact with relatives, unintentional weight loss in the past 6 months, body mass index, self-rated health, functional disability and depressive symptoms.
$\ddagger$ Adjusted for sex and all variables above.
limitation as all the subjects were attendees at a primary care facility. The Elderly Health Centres tend to attract healthier clients who voluntarily come to the clinics, so the risks of smoking in the general elderly population in Hong Kong might be underestimated. As the Cohen effect sizes for baseline demographic characteristics and proportionate mortality were small, this bias should not be substantial.
Our study had several strengths. The mortality data are available from the death registry database, which is checked regularly by the Department of Health. Records were linked using the unique Hong Kong identification number. Almost all deaths in Hong Kong are certified by doctors in the hospital, and validity and completeness of the causes of death should be good, especially within the broad categorisation that we are using for the causes of death. Hong Kong Death Registry data have been used in many studies and have been found to be of good quality. ${ }^{14}$ The sample size was large and we had a large number of current smokers and former smokers, especially women, which allowed us to conduct separate analyses for each sex and test the effect of quitting. The successful follow-up rate was higher and we adjusted for more potential confounders than previous studies.
In conclusion, the present study showed significantly higher risks of death from all causes, cancer, CVDs and respiratory diseases among current smokers and former smokers for both

## What this paper adds

- Smoking kills; however, the harms of smoking and the benefits of quitting are not well established in older Chinese.
- Older Chinese male and female smokers and ex smokers had higher risks of dying.
- Quitters had significantly lower risks of death than currents smokers.
- Smoking cessation is urgently needed in rapidly ageing populations in the East.
male and female older people in Hong Kong, and quitting smoking was beneficial in reducing these risks. Smoking cessation, including in elderly smokers, should be an urgent public health priority in Hong Kong and also in other developing countries, especially in mainland China and in other rapidly ageing populations in the East.


## ACKNOWLEDGEMENTS

We thank the staff of the elderly health centres and the Hospital Authority for their assistance in data collection and entry.

## Authors' affiliations

Tai Hing Lam, Zhi Bin Li, Sai Yin Ho, Benjamin J Cowling, C Mary
Schooling, Gabriel M Leung, Department of Community Medicine, School of Public Health, The University of Hong Kong, Pokfulam, Hong Kong
Wai Man Chan, Kin Sang Ho, May Ked Tham, Department of Health, The Government of the Hong Kong Special Administrative Region, Hong Kong, Hong Kong
Funding: This project was funded by the Health Care \& Promotion Fund Committee in Hong Kong (Grant HSRC\#S111016).

Competing interests: None.

## REFERENCES

1 Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. BMJ 1976;2:1525-36.
2 Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994;309:901-1 1.
3 Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004;328:1519-27.
4 Yang G, Fan L, Tan J, et al. Smoking in China: findings of the 1996 National Prevalence Survey. JAMA 1999;282:1247-53.
5 Yuan JM, Ross RK, Wang XL, et al. Morbidity and mortality in relation to cigarette smoking in Shanghai, China. A prospective male cohort study. JAMA 1996;275:1646-50.
6 Chen ZM, Xu Z, Collins R, et al. Early health effects of the emerging tobacco epidemic in China. A 16-year prospective study. JAMA 1997;278:1500-4.
7 Lam TH, He Y, Li LS, et al. Mortality attributable to cigarette smoking in China. JAMA 1997;278:1505-8.
8 Niu SR, Yang GH, Chen ZM, et al. Emerging tobacco hazards in China: 2. Early mortality results from a prospective study. BMJ 1998;317:1423-4.
9 Lam TH, He Y, Shi QL, et al. Smoking, quitting, and mortality in a Chinese cohort of retired men. Ann Epidemiol 2002;12:316-20.
10 LaCroix AZ, Lang J, Scherr P, et al. Smoking and mortality among older men and women in three communities. N Engl J Med 1991;324:1619-25.

11 Vogt MT, Cauley JA, Scott JC, et al. Smoking and mortality among older women: the study of osteoporotic fractures. Arch Intern Med 1996;156:630-6.
12 Millar S. Hong Kong Human Ecology Programme, The biosocial survey in Hong Kong. Canberra: Central Printery, Australian National University, 1979.
13 Mackay JM, Barnes GT. Effects of strong government measures against tobacco in Hong Kong. BMJ 1986;292:1435-7.
14 Lam TH, Ho SY, Hedley AJ, et al. Mortality and smoking in Hong Kong: casecontrol study of all adult deaths in 1998. BMJ 2001;323:361-6.
15 Ho SC, Zhan SY, Tang JL, et al. Smoking and mortality in an older Chinese cohort. J Am Geriatr Soc 1999;47:1445-50.
16 Li ZB, Ho SY, Chan WM, et al. Obesity and depressive symptoms in Chinese elderly. Int J'Geriatr Psychiatry 2004;19:68-74.
17 Schooling CM, Lam TH, Li ZH, et al. Obesity, physical activity and mortality in a prospective Chinese elderly cohort. Arch Intern Med 2006;166:1498-504.
8 Andersen PK, Abildstrom SZ, Rosthoi S. Competing risks as a multi-state model. Stat Methods Med Res 2002;11:203-15.
19 Satagopan JM, Ben-Porat L, Berwick M, et al. A note on competing risks in survival data analysis. $\mathrm{Br} J$ Cancer 2004;91:1229-35.
20 Cohen J. Statistical power analysis for the behavioral sciences, 2nd edn. Hillsdale, NJ: Lawrence Earlbaum Associates, 1988.
21 Centers for Disease Control and Prevention. The health consequences of smoking: a report of the surgeon general, Office on Smoking and Health, 2004.

22 LaCroix AZ, Omenn GS. Older adults and smoking. Clin Geriatr Med 1992;8:69-87
23 Paganini-Hill A, Hsu G. Smoking and mortality among residents of a California retirement community. Am J Public Health 1994;84:992-5.
24 Harris T, Cook EF, Kannel WB, et al. Proportional hazards analysis of risk factors for coronary heart disease in individuals aged 65 or older. The Framingham Heart Study. J Am Geriatr Soc 1988;36:1023-8.
25 Peto R, Chen ZM, Boreham J. Tobacco-the growing epidemic. Nat Med 1999;5:15-17.
26 Liu BQ, Peto R, Chen ZM, et al. Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ 1998;317:1411-22.
27 Cupples LA, D'Agostino RB. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements: Framingham Heart Study, 30-year follow-up, Section 34 of the Framingham Study:an epidemiological investigation of cardiovascular disease. Bethesda, MD: National Institute of Health, 1987.
28 Abbott RD, Yin Y, Reed DM, et al. Risk of stroke in male cigarette smokers. N Engl J Med 1986;315:717-20.
29 Wolf PA, D'Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA 1988;259:1025-9.
30 US Department of Health and Human Services. The health benefits of smoking cessation. Rockville, MD: Department of Health and Human Services, 1990.


[^0]:    CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease.

    * $p<0.05, ~ * * p<0.01, ~ * * * p<0.001$.
    $\dagger$ Linear trend with increasing smoking status from never, former and current smokers.
    $\ddagger$ linear trend with increasing smoking status from never smoker, former smoker and current smoker who consumed $1-9,10-20$ and $\geqslant 21$ cigarettes daily.
    §Combining current smoker and former smoker.
    - Adjusted for age, education, alcohol consumption, physical exercise and active chronic diseases: hypertension, diabetes mellitus, heart diseases, COPD/asthma, hypercholesterolaemia, cerebrovascular accident, regular medication, admission to hospital, monthly expenditure, regular contact with relatives, unintentional weight loss in the past 6 months, body mass index, self-rated health, functional disability and depressive symptoms.

